Kidney Cancer Journal 127 EDITORIAL ADVISORY BOARD Michael B. Atkins, MD Lombardi Comprehensive Cancer Center Professor of Oncology and Medicine, Georgetown University Medical Center- Washington, DC Arie Belldegrun, MD David Geffen School of Medicine at UCLA Los Angeles, California Steven Campbell, MD Cleveland Clinic Foundation Cleveland, Ohio Toni K. Choueiri, MD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts Janice P. Dutcher, MD Associate Director, Cancer Research Foundation of New York Chappaqua, New York Timothy Eisen, MD University of Cambridge Department of Oncology, Addenbrooke's Hospital Cambridge, UK Paul Elson, PhD Cleveland Clinic Foundation Cleveland, Ohio Bernard Escudier, MD Institut Gustave-Roussy Villejuif, France James H. Finke, PhD Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Cleveland, Ohio Keith T. Flaherty, MD Lecturer, Department of Medicine, Harvard Medical School Director of Developmental Therapeutics, Cancer Center Massachusetts General Hospital Boston, Massachusetts Daniel J. George, MD Duke Clinical Research Institute Durham, North Carolina Inderbir S. Gill, MD USC Institute of Urology University of Southern California Los Angeles, California Martin Gore, MD Royal Marsden Hospital London, UK Gary Hudes, MD Fox Chase Cancer Center Philadelphia, Pennsylvania Thomas Hutson, DO, PharmD Baylor University Medical Center Dallas, Texas Eric Jonasch, MD University of Texas MD Anderson Cancer Center Houston, Texas Eugene D. Kwon, MD Mayo Clinic Rochester, Minnesota Bradley C. Leibovich, MD Mayo Clinic Rochester, Minnesota David Nanus, MD New York Presbyterian Hospital- Weill Cornell Medical Center New York, New York Leslie Oleksowicz, MD College of Medicine University of Cincinnati Medical Center Cincinnati, Ohio Allan Pantuck, MD David Geffen School of Medicine at UCLA Los Angeles, California W. Kimryn Rathmell, MD, PhD Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill, North Carolina Brian Rini, MD Cleveland Clinic Foundation Cleveland, Ohio Paul Russo, MD Memorial Sloan-Kettering Cancer Center New York, New York Ihor S. Sawczuk, MD Hackensack University Medical Center Hackensack, New Jersey Domenic A. Sica, MD Medical College of Virginia Richmond, Virginia Jeffrey A. Sosman, MD Vanderbilt University Medical Center Vanderbilt-Ingram Cancer Center Nashville, Tennessee Nicholas J. Vogelzang, MD Comprehensive Cancer Centers of Nevada Las Vegas, Nevada Kidney Cancer Journal Author Guidelines Scope of Manuscripts The Kidney Cancer Journal considers the following types of manuscripts for publication: • Reviews that summarize and synthesize peer-reviewed literature to date on relevant topics in a scholarly fashion and format. • Original contributions based on original, basic, clinical, translational, epidemiological, or prevention studies relating to kidney cancer that are well documented, novel, and significant. • Letters to the Editor on timely and relevant subjects pertaining to the diagnosis and treatment of renal cell carcinoma. • Clinical case studies. Manuscript Submission Authors are required to submit their manuscripts in an electronic format, preferably by email to the Editor-in-Chief, Robert A. Figlin, MD, at rfiglin@coh.org. Please provide in a word processing program. Images should be submitted electronically as well. All material reproduced from previously published, copyrighted material should contain a full credit line acknowledging the original source. The author is responsible for obtaining this permission. Contact information List all authors, including mailing address, titles and affiliations, phone, fax, and email. Please note corresponding author. Peer Review and Editing Manuscripts will be peer reviewed. Accepted manuscripts will be edited for clarity, spelling, punctuation, grammar, and consistency with American Medical Association (AMA) style. Authors whose manuscripts are not initially accepted may have the opportunity to revise the manuscript based on recommendations from peer reviewers and at the discretion of the Editor-in-Chief. Conflict of Interest Kidney Cancer Journal policy requires that authors reveal to the Editor-in-Chief any relationships that they believe could be construed as resulting in an actual, potential, or apparent conflict of interest with regard to the manuscript submitted for review. Authors must disclose this information in the covering letter accompanying their submission. Manuscript Preparation Length: Full-length manuscripts should not exceed 4000 words, including references. Please limit the reference list to 50 citations. Manuscripts should be accompanied by figures and/or tables. Generally 4-5 figures and 2-3 tables are preferred for each manuscript. Please include a brief description to accompany these items, as well as a legend for all abbreviations. Manuscripts should not contain an abstract but an introduction is recommended. Spacing: One space after periods. Manuscripts should be double spaced. References All submissions should have references that are referred to in the text by superscripted numbers and that conform to AMA style. Example: Lewczuk J, Piszko P, Jagas J, et al. Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest. 2001;119:818-823. Copyright Manuscripts and accompanying material are accepted for exclusive publication in the Kidney Cancer Journal. None of the contents may be reproduced without permission of the Kidney Cancer Journal. To request permission, please contact Stu Chapman, Executive Editor, (516) 356-5006; email: stulink@aol.com.
19544GA
To see the actual publication please follow the link above